Estimation of SARS-CoV-2 Infection Fatality Rate by Age and Comorbidity Status Using Antibody Screening of Blood Donors During the COVID-19 Epidemic in Denmark.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
18 01 2022
Historique:
received: 25 07 2021
accepted: 09 11 2021
pubmed: 18 11 2021
medline: 27 1 2022
entrez: 17 11 2021
Statut: ppublish

Résumé

Studies presenting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR) for healthy individuals are warranted. We estimate IFR by age and comorbidity status using data from a large serosurvey among Danish blood donors and nationwide data on coronavirus disease 2019 (COVID-19) mortality. Danish blood donors aged 17-69 years donating blood October 2020-February 2021 were tested with a commercial SARS-CoV-2 total antibody assay. IFR was estimated for weeks 11 to 42, 2020 and week 43, 2020 to week 6, 2021, representing the first 2 waves of COVID-19 epidemic in Denmark. In total, 84944 blood donors were tested for antibodies. The seroprevalence was 2% in October 2020 and 7% in February 2021. Among 3898039 Danish residents aged 17-69 years, 249 deaths were recorded. The IFR was low for people <51 years without comorbidity during the 2 waves (combined IFR=3.36 per 100000 infections). The IFR was below 3‰ for people aged 61-69 years without comorbidity. IFR increased with age and comorbidity but declined from the first to second wave. In this nationwide study, the IFR was very low among people <51 years without comorbidity.

Sections du résumé

BACKGROUND
Studies presenting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR) for healthy individuals are warranted. We estimate IFR by age and comorbidity status using data from a large serosurvey among Danish blood donors and nationwide data on coronavirus disease 2019 (COVID-19) mortality.
METHODS
Danish blood donors aged 17-69 years donating blood October 2020-February 2021 were tested with a commercial SARS-CoV-2 total antibody assay. IFR was estimated for weeks 11 to 42, 2020 and week 43, 2020 to week 6, 2021, representing the first 2 waves of COVID-19 epidemic in Denmark.
RESULTS
In total, 84944 blood donors were tested for antibodies. The seroprevalence was 2% in October 2020 and 7% in February 2021. Among 3898039 Danish residents aged 17-69 years, 249 deaths were recorded. The IFR was low for people <51 years without comorbidity during the 2 waves (combined IFR=3.36 per 100000 infections). The IFR was below 3‰ for people aged 61-69 years without comorbidity. IFR increased with age and comorbidity but declined from the first to second wave.
CONCLUSIONS
In this nationwide study, the IFR was very low among people <51 years without comorbidity.

Identifiants

pubmed: 34788834
pii: 6426172
doi: 10.1093/infdis/jiab566
pmc: PMC8689980
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

219-228

Subventions

Organisme : Central Denmark Region
Organisme : Danish Health Authority
Organisme : Novo Nordisk Foundation
ID : NNF17OC0027864

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Auteurs

Kathrine Agergård Kaspersen (KA)

Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
Danish Big Data Centre for Environment and Health, Aarhus University, Roskilde, Denmark.

Lotte Hindhede (L)

Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.

Jens Kjærgaard Boldsen (JK)

Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
Danish Big Data Centre for Environment and Health, Aarhus University, Roskilde, Denmark.

Susan Mikkelsen (S)

Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.

Lasse Skafte Vestergaard (LS)

Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark.

Ann-Sofie Nicole Berthelsen (AN)

Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark.

Ida Rask Moustsen-Helms (IR)

Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark.

Dorte Kinggaard Holm (DK)

Department of Clinical Immunology, Odense University Hospital, Odense, Denmark.

Anna Christine Nilsson (AC)

Department of Clinical Immunology, Odense University Hospital, Odense, Denmark.

Susanne Gjørup Sækmose (SG)

Department of Clinical Immunology, Zealand University Hospital, Naestved, Denmark.

Erik Sørensen (E)

Department of Clinical Immunology, Copenhagen University Hospital, Copenhagen, Denmark.

Lene Holm Harritshøj (LH)

Department of Clinical Immunology, Copenhagen University Hospital, Copenhagen, Denmark.

Bitten Aagaard (B)

Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark.

Henrik Hjalgrim (H)

Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.

Søren Thue Lillevang (ST)

Department of Clinical Immunology, Odense University Hospital, Odense, Denmark.

Charlotte Sværke Jørgensen (CS)

Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark.

Tyra Grove Krause (TG)

Infectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark.

Henrik Ullum (H)

Statens Serums Institut, Copenhagen, Denmark.

Ole Birger Vestager Pedersen (OBV)

Department of Clinical Immunology, Zealand University Hospital, Naestved, Denmark.
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Sisse Rye Ostrowski (SR)

Department of Clinical Immunology, Copenhagen University Hospital, Copenhagen, Denmark.
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Christian Erikstrup (C)

Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH